Marksans Pharma Ltd logo

Marksans Pharma Ltd

MARKSANS NSE

Key Fundamentals

SmallcapPharmaceuticalsHealthcare
Market Cap
₹15,160 Cr
Volatility
High Risk
P/E Ratio
28.71
EBITDA
₹683 Cr
Return on Equity
13.76%
Debt to Equity
0.11
Book Value
₹66.71
EPS
₹7.37
52W High
₹345.5
52W Low
₹155

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Marksans Pharma Ltd insights

51 extracted metrics + investor summaries across FY15–FY26.

Log in — free

Tapetide Score

Data-driven rating, 0–100. How it works →

Technical Indicators

Growth Rate

Revenue Growth
12.80% ↗
Net Income Growth
9.80% ↗
Cash Flow Change
121.68% ↗
ROE
-10.47% ↘
ROCE
-6.05% ↘
EBITDA Margin (Avg.)
1.17% ↘

AI Analysis — Bull vs Bear

Anthropic anthropic claude-opus-4.6 4d ago
AI opinion · based on fundamentals
Risk medium

Marksans Pharma is a mid-cap pharmaceutical company with a market cap of approximately ₹13,979 crore, trading at a P/E of 27.2x. The company has delivered consistent double-digit revenue growth (17% CAGR over 3 years, 20% TTM) with profit growth accelerating to 48% TTM, and operates with a low debt-to-equity ratio of around 0.11. Its stock has appreciated 70% over the past year, significantly outpacing its historical earnings growth rates.

Bull Case 8
  • Strong TTM profit growth of 48% significantly outpaces the 3-year profit CAGR of 16%, indicating an acceleration in earnings momentum
  • Consistent revenue compounding at 17% over 3 years and 16% over 5 years demonstrates durable top-line growth in regulated pharma markets
  • Very low debt-to-equity ratio of ~0.11x provides financial flexibility and reduces balance sheet risk
  • Cash balance crossed ₹1,000 crore for the first time in Q1 FY27, indicating strong free cash flow generation
  • FY26 annual revenue crossed ₹2,951 crore (12.5% YoY growth) with record-high EBITDA and PAT, showing operational scale-up
  • Return on equity has been stable at 15-17% over 3, 5, and 10-year periods, reflecting consistent capital efficiency
  • 10-year revenue CAGR of 13% and profit CAGR of 18% demonstrate a long track record of compounding in a defensive healthcare sector
  • Q1 FY27 revenue of ₹840.8 crore grew 35.6% YoY with record EBITDA and PAT, suggesting growth acceleration continues into FY27
Bear Case 8
  • P/E of 27.2x is elevated relative to the 5-year profit CAGR of only 12%, implying the stock prices in significant future acceleration
  • Stock has surged 70% in 1 year versus TTM profit growth of 48%, suggesting price has run ahead of fundamentals
  • Price-to-book ratio of 4.69x is high for a generic pharma company with 15% ROE, limiting margin of safety
  • Dividend yield of just 0.29% offers minimal income return to shareholders despite strong cash generation
  • Q1 FY27 revenue of ₹840.8 crore missed analyst expectations by 4.28%, and the stock fell 3% post-results, indicating high expectations are already embedded
  • 3-year stock CAGR of 40% far exceeds the 3-year profit CAGR of 16%, suggesting multiple expansion that may not sustain
  • ROE declined from 17% (5-year average) to 15% in the last year despite rising profits, possibly due to growing equity base from retained earnings
  • Company operates in competitive OTC and generic Rx segments in regulated markets where pricing pressure and regulatory risk remain ongoing concerns

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

Anthropic anthropic claude-opus-4.6 16h ago
Positives 3
  • Q1FY26 PAT surges 174% YoY Aug 12

    Consolidated net profit of ₹1,594.07 million in Q1FY26, up 174% YoY, driven by revenue growth to ₹8,407.96 million and forex gains.

  • ABCnow GmbH acquisition completed Jul 20

    Marksans completed 100% acquisition of Germany-based ABCnow GmbH on July 20, 2026, expanding its European footprint.

  • QliniQ B.V. acquisition added Aug 12

    Alongside ABCnow, the company also acquired QliniQ B.V. during Q1FY26, strengthening its inorganic growth strategy.

Neutral 3
  • 34th AGM scheduled Aug 27 Jul 30

    AGM to be held on August 27, 2026 via VC/OAVM. Newspaper notices published on July 30 and August 6 per SEBI regulations.

  • FY26 BRSR report filed Aug 4

    Submitted Business Responsibility and Sustainability Report for FY26 to exchanges, covering ESG metrics and governance structures.

  • Q1FY27 earnings call scheduled Aug 3

    Management to host Q1FY27 earnings conference call on August 13, 2026 at 4:30 PM IST to discuss unaudited results.

TL;DR: Marksans Pharma is firing on all cylinders with a 174% YoY profit jump in Q1FY26 and two European acquisitions (QliniQ B.V. and ABCnow GmbH) signaling aggressive inorganic expansion. No material headwinds are visible in recent news flow. The trend is clearly improving with strong earnings momentum and geographic diversification into Europe positioning the company for sustained growth.

Quarterly Results

  Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
500
531
586
560
591
642
682
708
620
720
754
856
841
Expenses
398
417
453
450
462
495
543
582
520
576
594
661
628
Operating Profit
102
114
133
110
128
147
139
127
100
144
161
195
213
OPM %
20%
21%
23%
20%
22%
23%
20%
18%
16%
20%
21%
23%
25%
Other Income
10
19
5
17
15
0
28
15
6
22
20
35
25
Interest
2
2
3
5
3
3
3
3
6
6
6
6
7
Depreciation
14
18
22
21
20
20
21
23
23
27
24
24
25
PBT
97
114
113
100
120
125
143
116
77
133
151
200
207
Tax %
27%
26%
26%
23%
26%
22%
27%
22%
24%
26%
25%
25%
23%
Net Profit
70
84
83
78
89
98
105
91
58
99
114
149
159
EPS in Rs
1.52
1.84
1.84
1.73
1.96
2.13
2.31
2
1.29
2.17
2.5
3.27
3.47
Figures in ₹ Crores

Profit & Loss

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
797
893
767
913
1,000
1,134
1,376
1,491
1,852
2,177
2,623
2,951
3,172
Expenses
612
757
722
834
868
942
1,037
1,232
1,513
1,719
2,090
2,350
2,458
Operating Profit
185
136
45
78
132
192
340
259
340
459
533
601
714
OPM %
23%
15%
6%
9%
13%
17%
25%
17%
18%
21%
20%
20%
22%
Other Income
3
9
7
8
5
0
7
42
59
50
66
82
102
Interest
16
10
7
10
10
9
8
8
9
11
12
24
25
Depreciation
16
28
30
27
23
27
36
45
52
74
83
99
100
PBT
156
107
15
50
104
157
302
248
338
424
504
561
691
Tax %
28%
23%
24%
28%
23%
23%
21%
25%
21%
26%
24%
25%
—
Net Profit
112
83
11
36
80
121
239
187
265
315
383
420
521
EPS in Rs
2.67
1.92
0.22
0.8
1.87
2.95
5.76
4.51
5.88
6.92
8.4
9.22
11.41
Div. Payout %
4%
21%
23%
6%
3%
3%
4%
6%
9%
9%
10%
10%
—
Figures in ₹ Crores

Balance Sheet

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
41
41
41
41
41
41
41
41
45
45
45
45
Reserves
326
401
392
430
502
595
846
1,161
1,700
2,020
2,422
2,978
Borrowings
101
100
110
118
100
30
34
111
123
244
322
343
Other Liabilities
207
180
209
142
160
236
307
323
322
372
451
489
Total Liabilities
676
722
752
731
802
902
1,228
1,636
2,190
2,681
3,240
3,856
Fixed Assets
166
270
267
279
270
303
309
428
486
776
982
1,044
CWIP
0
0
0
0
0
0
12
3
10
9
27
59
Investments
0
0
0
0
0
0
0
0
1
27
1
0
Other Assets
510
452
484
451
533
599
907
1,205
1,694
1,869
2,230
2,753
Total Assets
676
722
752
731
802
902
1,228
1,636
2,190
2,681
3,240
3,856
Figures in ₹ Crores

Cash Flow

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
155
31
14
50
27
233
179
99
237
230
207
458
Investing
-33
-123
-21
-39
-13
-60
-45
-84
-259
-141
-49
-249
Financing
17
-58
-3
3
-21
-114
-15
80
198
-69
-65
-71
Net Cash Flow
138
-150
-10
15
-7
60
118
94
176
21
93
138
Free Cash Flow
118
-101
-14
11
14
174
133
53
184
22
35
329
CFO/OP
108
43
31
73
41
134
67
66
88
77
62
99
Figures in ₹ Crores

Ratios

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
84
89
118
71
64
78
72
97
82
76
75
80
Inventory Days
107
120
151
152
215
155
248
216
192
217
270
278
Days Payable
88
85
129
54
78
71
103
102
91
94
98
96
Cash Conversion Cycle
103
124
140
169
202
163
217
211
183
199
247
261
Working Capital Days
17
59
77
70
97
87
104
121
122
129
142
149
ROCE %
44%
23%
4%
10%
18%
25%
38%
23%
22%
21%
20%
19%

Shareholding Pattern

As of Jun 2026
Promoters 43.87%
Public 28.05%
FIIs 17.47%
DIIs 6.19%
Others 4.42%
Total 100.00%
  Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Jan 2023Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters
48.25%
48.25%
48.25%
48.25%
48.25%
48.25%
48.60%
49.00%
43.80%
43.85%
43.85%
43.85%
43.85%
43.85%
43.87%
43.87%
43.87%
43.87%
43.87%
43.87%
43.87%
43.87%
43.87%
FIIs
1.00%
0.59%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
10.88%
10.88%
10.88%
10.88%
10.88%
15.57%
18.60%
21.31%
21.96%
22.20%
19.88%
16.92%
8.12%
16.76%
17.47%
DIIs
0.09%
0.34%
0.34%
0.34%
0.46%
0.95%
0.95%
0.96%
0.87%
1.46%
3.65%
3.15%
3.82%
5.17%
3.75%
4.10%
4.30%
4.56%
5.50%
5.28%
5.91%
6.57%
6.19%
Government
0.00%
0.00%
0.00%
0.00%
0.15%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
Public
41.50%
41.71%
42.41%
42.47%
41.36%
40.77%
39.76%
39.69%
35.19%
34.42%
32.36%
32.12%
30.80%
30.91%
29.47%
26.77%
26.24%
25.77%
26.75%
29.53%
28.98%
28.33%
28.05%
Others
9.15%
9.11%
9.00%
8.94%
9.78%
10.04%
10.69%
10.34%
9.25%
9.39%
9.25%
10.00%
10.64%
4.49%
4.31%
3.95%
3.63%
3.59%
4.00%
4.40%
13.11%
4.45%
4.42%
No. of Shareholders
0
1,35,271
1,88,888
2,01,451
2,14,998
2,20,090
2,21,359
2,17,743
2,13,123
1,98,382
1,88,447
2,07,937
2,37,377
2,54,699
2,35,500
2,48,845
2,59,813
2,57,273
2,56,221
2,65,788
2,55,153
2,46,279
2,46,635

Documents

1
Concall - Aug 2019 Aug 2019
2
Concall - Aug 2019 Aug 2019
3
Concall - Feb 2020 Feb 2020
4
Concall - Jun 2020 Jun 2020
5
Concall - Aug 2020 Aug 2020

Frequently Asked Questions about Marksans Pharma Ltd

What does Marksans Pharma Ltd do?
Marksans Pharma is engaged in the Business of Formulation of pharmaceutical products [1]
Where is Marksans Pharma Ltd (MARKSANS) listed?
Marksans Pharma Ltd is listed on the Indian stock exchanges. It is listed on NSE: MARKSANS and BSE: 524404. You can view its live share price, financials, and ratios on Tapetide.
Which sector does Marksans Pharma Ltd belong to?
Marksans Pharma Ltd operates in the Healthcare sector within the Pharmaceuticals industry. Sector classification helps investors compare companies affected by similar economic conditions and regulatory changes.
What is the market capitalisation of Marksans Pharma Ltd?
Marksans Pharma Ltd has a market capitalisation of approximately ₹15160.23 Cr. Based on this, it is classified as a Mid Cap stock.
What is the PE ratio of Marksans Pharma Ltd?
The Price-to-Earnings (PE) ratio of Marksans Pharma Ltd is 28.71. The PE ratio compares a company's share price to its earnings per share and is commonly used to assess whether a stock is overvalued or undervalued relative to its peers.
What is the 52-week high and low of Marksans Pharma Ltd?
Over the past 52 weeks, Marksans Pharma Ltd has traded between a low of ₹155 and a high of ₹345.5. This range helps investors understand the stock's price volatility and recent trading levels.
Does Marksans Pharma Ltd pay dividends?
Yes, Marksans Pharma Ltd has a dividend yield of 0.27%. Dividend yield indicates the annual dividend income relative to the share price. A consistent dividend history can signal financial stability.
What is the Return on Equity (ROE) of Marksans Pharma Ltd?
Marksans Pharma Ltd has a Return on Equity (ROE) of 13.76%. ROE measures how effectively a company uses shareholders' equity to generate profits. A higher ROE generally indicates better capital efficiency.
How can I research Marksans Pharma Ltd on Tapetide?
On Tapetide, you can view Marksans Pharma Ltd's live share price, quarterly results, profit & loss statements, balance sheet, cash flow, key ratios, shareholding pattern, technical indicators, analyst ratings, and forecasts — all on a single page without needing to sign up.

Company Information

Marksans Pharma is engaged in the Business of Formulation of pharmaceutical products [1]

Website marksanspharma.com
CEO Mr. Mark B. Saldanha
Employees 1,840
Listed 2002-01-21
Face Value ₹ 1
Issued Size 45,31,63,746

Explore More

More in Healthcare → FII DII Data Stock Screener Nifty 50 Heatmap F&O Ban List